Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785789 | 0.76 | BACE1 (0.36) | S1PR1S1PR3ADRA2AADRA2BADRA2C | |
| SCHEMBL3376187 | 0.75 | ADRA2A (0.35) | ADRB2ADRB1HTR1AOPRK1S1PR1 | |
| SCHEMBL20373858 | 0.72 | NISCH (0.42) | S1PR1S1PR3ADRA2AADRA2BADRA2C | |
| SCHEMBL7737243 | 0.71 | PARP1 (0.35) | ADRB2ADRB1HTR1AOPRK1S1PR1 | |
| SCHEMBL31161854 | 0.71 | RET (0.32) | S1PR1S1PR3 | |
| SCHEMBL3373757 | 0.70 | HTR1A (0.43) | ADRB2ADRB1HTR1AOPRK1 | |
| SCHEMBL15311619 | 0.70 | NOTUM (0.37) | HTR1AS1PR1S1PR3 | |
| SCHEMBL14842638 | 0.68 | ADRA2A (0.35) | HTR1AADRA2AADRA2BADRA2CNISCH | |
| SCHEMBL31158955 | 0.67 | HSD11B1 (0.41) | HTR1AADRA2A | |
| SCHEMBL927341 | 0.67 | HSD11B1 (0.41) | HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757585-B1 | Anionically substituted 7-Nitroindoline derivatives and their uses | MEDICAL RES COUNCIL (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-7737169-B2 | Anionically substituted 7-nitroindoline derivatives and their uses | MEDICAL RESEARCH COUNCIL (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1757585-A1 | Anionically substituted 7-Nitroindoline derivatives and their uses | Medical Research Council (GB) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | SLC18A3, SLC18A1, SLC18A2 | ADRB2 191/4885ADRB1 237/4885HTR1A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.